Cardiovascular Diseases Clinical Trial
To determine if silent myocardial ischemia was associated with an increased risk of cardiac mortality and morbidity during a one to three year follow-up in patients with coronary heart disease.
BACKGROUND:
Reports of unsuspected, frequent and prolonged episodes of asymptomatic ST depression (ASTD)
raised important issues for the evaluation and treatment of coronary disease. The
traditional role of angina as the best indicator of myocardial ischemia had to be
reevaluated, since several studies had shown that ASTD was much more frequent than
symptomatic ischemia in many patients with coronary disease. If ASTD reflected clinically
meaningful ischemia, then overt angina represented only 25 percent of the total ischemic
burden. Moreover, incomplete data suggested that an increased and clinically unsuspected
risk might be conferred on a patient with frequent episodes of ASTD. In 1988, studies were
already in progress to find the most effective drug for treating ASTD. If no increased risk
was associated with asymptomatic myocardial ischemia, there was little value in pursuing
further investigations into its detection and therapy. But if the risk was increased, the
detection and treatment of asymptomatic as well as symptomatic myocardial ischemia might
completely alter therapy and the outlook for patients with coronary disease. The information
in 1988 on the increased risk of ASTD was unfortunately scattered and sparse.
DESIGN NARRATIVE:
A total of 973 patients were enrolled two to six months after hospitalization for an acute
coronary event. Patients were derived from geographically dispersed centers to enhance
generalization of the results to the overall population at risk. Ambulatory 24-hour Holter
electrocardiographic recordings were used to evaluate the frequency, severity, and duration
of asymptomatic ST depression (ASTD) as a marker of silent myocardial ischemia during usual
daily activities. This information was analyzed in conjunction with ST segment depression on
treadmill exercise, reversible myocardial perfusion defects on stress thallium testing, and
a limited number of prespecified clinical parameters to assess the contribution which ASTD
added to prognostic information from then current diagnostic techniques used to evaluate
myocardial ischemia. Patients were seen by the study coordinator every four months during
the first year, then every six months thereafter. At each visit the study coordinator
interviewed patients to determine interim history, functional status symptoms, and drug
usage. At the four month visit a second 24-hour Holter recording was obtained. At the
12-month visit and at study termination, 12-lead electrocardiograms were recorded and sent
to the ECG Core Laboratory for analysis. Data analyses were used: to assess the predictive
usefulness and independence of ASTD in ambulatory patients with established coronary heart
disease; to evaluate the interactions and associations between the frequency, severity, and
duration of ASTD and other measures of myocardial ischemia; to obtain insight into suspected
vasoactive and increased myocardial oxygen consumption mechanisms of myocardial ischemia; to
better understand the interrelationship between myocardial ischemia and ventricular
arrhythmias as it related to subsequent cardiac mortality and morbidity.
The study was renewed in 1993 for one year in order to fully analyze the prospectively
accumulated data on the 973 enrolled patients in the Multicenter Study of Silent Myocardial
Ischemia (MSSMI). The primary goal was to determine the usefulness, or the lack thereof, of
ambulatory electrocardiographic (AECG) monitoring for identifying coronary patients with
jeopardized ischemic myocardium at risk for ischemic cardiac events. The aims of the study
were: 1) to evaluate the reproducibility of then current methods for detecting ischemic-type
changes (ST depression) on AECG; 2) to improve the accuracy and reliability of contemporary
scanner-interactive methodology that had been utilized for identifying ischemic-type
ST-segment changes on the AECG; 3) to complete the development on a new, innovative, and
reproducible computer-based technique for automatic (operator-independent), quantitative
identification of beat-to-beat ischemic-type ST depression on the MSSMI AECG tapes; 4) to
evaluate the clinical utility of the improved and new ST-segment analytic techniques to
identify coronary patients at risk for natural cardiac events (unstable angina, non-fatal
myocardial infarction, and cardiac death) during two year follow-up in the overall MSSMI
population, in selected subgroups (gender, age), and in prespecified high-risk ischemic
subsets; and 5) to determine the optimal cost- effective strategy for sequencing the
assessment of silent, jeopardized ischemic myocardium by clinical variables and non-invasive
tests to identify coronary patients at risk for subsequent ischemic cardiac events. This
research utilized statistical techniques for evaluating reproducibility of detecting ST
depression on AECG (kappa statistics, analyses of variance, Cochran's Q-test), for
determining ischemic risk factors for time-to-cardiac events (Cox regression analyses), and
for cost-effectiveness analyses (receiver-operator characteristic curves).
Twenty-four clinical centers In United States, Canada, Israel, and Japan participated in the
study. There were also an ECG Core Lab, an Exercise Core Lab, a Holter Core Lab, a Thallium
Core Lab, and a Coordinating Center.
;
N/A
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05650307 -
CV Imaging of Metabolic Interventions
|
||
Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
Recruiting |
NCT04515303 -
Digital Intervention Participation in DASH
|
||
Completed |
NCT04056208 -
Pistachios Blood Sugar Control, Heart and Gut Health
|
Phase 2 | |
Recruiting |
NCT04417387 -
The Genetics and Vascular Health Check Study (GENVASC) Aims to Help Determine Whether Gathering Genetic Information Can Improve the Prediction of Risk of Coronary Artery Disease (CAD)
|
||
Not yet recruiting |
NCT06211361 -
Cardiac Rehabilitation Program in Patients With Cardiovascular Disease
|
N/A | |
Not yet recruiting |
NCT06032572 -
Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE)
|
N/A | |
Recruiting |
NCT04514445 -
The BRAVE Study- The Identification of Genetic Variants Associated With Bicuspid Aortic Valve Using a Combination of Case-control and Family-based Approaches.
|
||
Enrolling by invitation |
NCT04253054 -
Chinese Multi-provincial Cohort Study-Beijing Project
|
||
Completed |
NCT03273972 -
INvestigating the Lowest Threshold of Vascular bENefits From LDL Lowering With a PCSK9 InhibiTor in healthY Volunteers
|
N/A | |
Completed |
NCT03680638 -
The Effect of Antioxidants on Skin Blood Flow During Local Heating
|
Phase 1 | |
Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
Completed |
NCT04083846 -
Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of High-dose CKD-385 in Healthy Volunteers(Fed)
|
Phase 1 | |
Completed |
NCT04083872 -
Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of Highdose CKD-385 in Healthy Volunteers(Fasting)
|
Phase 1 | |
Completed |
NCT03619148 -
The Incidence of Respiratory Symptoms Associated With the Use of HFNO
|
N/A | |
Completed |
NCT03693365 -
Fluid Responsiveness Tested by the Effective Pulmonary Blood Flow During a Positive End-expiratory Trial
|
||
Completed |
NCT03466333 -
Postnatal Enalapril to Improve Cardiovascular fUnction Following Preterm Pre-eclampsia
|
Phase 2 | |
Completed |
NCT04082585 -
Total Health Improvement Program Research Project
|
||
Completed |
NCT05132998 -
Impact of a Comprehensive Cardiac Rehabilitation Program Framework Among High Cardiovascular Risk Cancer Survivors
|
N/A | |
Completed |
NCT05067114 -
Solutions for Atrial Fibrillation Edvocacy (SAFE)
|